We are live on ! Find out more
SANA icon

Sana Biotechnology

131 hedge funds and large institutions have $508M invested in Sana Biotechnology in 2023 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 50 increasing their positions, 31 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

61% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 31

1.58% less ownership

Funds ownership: 64.75% → 63.17% (-1.6%)

3% less funds holding

Funds holding: 135 → 131 (-4)

30% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 27

31% less capital inflows, than outflows

Capital inflows: $27.9M | Capital outflows: $40.5M

50% less funds holding in top 10

Funds holding in top 10: 4 → 2 (-2)

84% less call options, than puts

Call options by funds: $303K | Put options by funds: $1.94M

Holders
131
Holders Change
-4
Holders Change %
-2.96%
% of All Funds
1.91%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
19
Increased
50
Reduced
31
Closed
27
Calls
$303​K
Puts
$1.94​M
Net Calls
-⁠$1.64​M
Net Calls Change
-⁠$1.68​M

SANA Hedge Fund Activity: Q4 2023 in Review

131 of the 6,876 institutional investors tracked by Wall St. Rank reported a position in Sana Biotechnology (SANA) for Q4 2023, worth a combined $508M — up 3% from $493M a quarter earlier.

Sellers outnumbered buyers: 27 funds closed out of SANA and 19 opened new positions — a net loss of 8 holders — while 31 trimmed existing stakes and 50 added.

The largest buyer was Millennium Management, adding an estimated $6.2M. The largest seller was T. Rowe Price Associates, cutting an estimated $12.6M.

  • 131 institutional investors held Sana Biotechnology (SANA) as of Q4 2023, down from 135 in Q3 2023.
  • Funds reported $508M of Sana Biotechnology stock for Q4 2023, up 3% quarter-over-quarter.
  • 19 funds opened new Sana Biotechnology positions in Q4 2023 and 27 closed out, a net change of -8 holders.
  • The largest Sana Biotechnology buyer in Q4 2023 was Millennium Management, an estimated $6.2M added.
  • The largest Sana Biotechnology seller in Q4 2023 was T. Rowe Price Associates, an estimated $12.6M sold.

Based on aggregated 13F filings for Q4 2023.